Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03529942 |
Recruitment Status :
Completed
First Posted : May 18, 2018
Results First Posted : December 8, 2020
Last Update Posted : December 8, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis, Knee | Drug: FX006 32 mg | Phase 3 |
This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee. The study will be conducted in male and female patients who are ≥ 40 years of age.
Eligible patients who provide written consent and meet all entry criteria will undergo initial ultrasound examination and MRI with contrast of the index knee, and then receive a single IA injection of FX006 administered to the index knee at Baseline/Day 1. Patients will return to the clinic at Weeks 6 and 24 for an MRI with contrast of the index knee and other assessments. Patients must also have a blood sample drawn for Estimated Glomerular Filtration Rate (eGFR) testing within 30 days prior to the scheduled MRIs. In addition, a patient questionnaire will be administered and adverse events (AEs) and concomitant medication updates will be collected via telephone at Weeks 12 and 18.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 129 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients With Osteoarthritis of the Knee |
Actual Study Start Date : | April 24, 2018 |
Actual Primary Completion Date : | November 8, 2019 |
Actual Study Completion Date : | March 9, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: FX006 32 mg
Single intra-articular (IA) injection of FX006 32 mg
|
Drug: FX006 32 mg
Extended-release 32 mg FX006 IA injection
Other Name: Zilretta |
- Mean Standardized Change in Synovial Volume (SV) at 6 Weeks [ Time Frame: Baseline to Week 6 ]Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.
- Mean Absolute Change in Synovial Volume at 6 Weeks [ Time Frame: Baseline to Week 6 ]Mean absolute change from baseline at 6 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.
- Mean Standardized Change in Synovial Volume (SV) at 24 Weeks [ Time Frame: Baseline to Week 24 ]Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.
- Mean Absolute Change in Synovial Volume at 24 Weeks [ Time Frame: Baseline to Week 24 ]Mean absolute change (mm^3) from baseline at 24 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written consent to participate in the study
- Male or female ≥ 40 years of age
- Body mass index (BMI) ≤ 40 kg/m^2
- Ambulatory and in good general health
- Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
- Willing to abstain from use of protocol-restricted medications during the study
- Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening (patient self-report is acceptable)
- Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA
- Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee based on X-ray performed during Screening (centrally read)
Exclusion Criteria:
- Any inflammatory arthritis including reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, gout or secondary OA from gout
- History of infection or crystal disease in the index knee joint
- Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of Screening
- Surgery or arthroscopy of the index knee within 12 months of Screening
- IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening
- IA treatment of the index knee with hyaluronic acid (investigational or marketed) within 6 months of Screening
- IV or IM corticosteroids (investigational or marketed) within 3 months of Screening
- Oral corticosteroids (investigational or marketed) within 1 month of Screening
- Any other IA drug/biologic in the index knee within 6 months of Screening or 5 half-lives (whichever is longer) (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy and amniotic fluid injection)
- Prior administration of FX006
- eGFR results <40 mL/minute
- Any contraindication to MRI Scanning (e.g., presence of certain ferromagnetic foreign bodies or electronic devices including most cardiac pacemakers, claustrophobia)
- Known hypersensitivity to any form of radiographic contrast
- Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03529942
United States, California | |
TriWest Research Associates, LLC | |
El Cajon, California, United States, 92020 | |
Biosolutions Research | |
La Mesa, California, United States, 91942 | |
Dream Team Clinical Research (formerly located in Anaheim) | |
Pomona, California, United States, 91767 | |
Dream Team Clinical Research | |
Pomona, California, United States, 91767 | |
United States, Florida | |
Tampa Bay Medical Research, Inc. | |
Clearwater, Florida, United States, 33761 | |
United States, Illinois | |
Rush University Medical Center | |
Chicago, Illinois, United States, 60612 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Pennsylvania | |
Altoona Center for Clinical Research | |
Duncansville, Pennsylvania, United States, 16635 | |
United States, Tennessee | |
PMG Research, Inc. d/b/a PMG Research of Knoxville | |
Knoxville, Tennessee, United States, 37938 | |
United Kingdom | |
University of Leeds | |
Leeds, United Kingdom, LS7 4SA |
Study Director: | Scott Kelley, MD | Flexion Therapeutics |
Documents provided by Flexion Therapeutics, Inc.:
Responsible Party: | Flexion Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT03529942 |
Other Study ID Numbers: |
FX006-2017-014 |
First Posted: | May 18, 2018 Key Record Dates |
Results First Posted: | December 8, 2020 |
Last Update Posted: | December 8, 2020 |
Last Verified: | December 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Osteoarthritis Knee Pain |
Intra-articular Injection Corticosteroid |
Osteoarthritis Osteoarthritis, Knee Inflammation Arthritis |
Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Pathologic Processes |